Loading patent…
AssigneeCellectis
InventorsRoman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
Estimating the term…
The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
A CD19 specific CAR comprising, in order from N-terminus to C-terminus:
An isolated T cell expressing on the cell surface a CD19 specific CAR comprising at least one extracellular ligand binding domain and at least one intracellular signaling domain, wherein the CD19 specific CAR expressed on the cell surface comprises the amino acid sequence of SEQ ID NO:15 without the signal peptide consisting of the amino acid sequence of SEQ ID NO:18.
An isolated T cell expressing on the cell surface a CD19 specific CAR comprising at least one extracellular ligand binding domain and at least one intracellular signaling domain, wherein the CD19 specific CAR expressed on the cell surface has at least 95% sequence identity with the amino acid sequence of SEQ ID NO:15;
Dependencies are inferred from the claim text.